🚀 VC round data is live in beta, check it out!
Dottikon ES Holding Valuation Multiples
Discover revenue and EBITDA valuation multiples for Dottikon ES Holding and similar public comparables like Cogent Biosciences, Shanghai Allist, Glenmark Pharma, Rhythm Pharmaceuticals and more.
Dottikon ES Holding Overview
About Dottikon ES Holding
Dottikon ES Holding AG manufactures high-quality performance chemicals, intermediates, and exclusive active pharmaceutical ingredients for the chemical and pharmaceutical industry.
Founded
1913
HQ
Employees
860
Website
Financials (LTM)
EV
$6B
Dottikon ES Holding Financials
Dottikon ES Holding reported last 12-month revenue of $581M and EBITDA of $212M.
In the same LTM period, Dottikon ES Holding generated $212M in EBITDA and $152M in net income.
Revenue (LTM)
Dottikon ES Holding P&L
In the most recent fiscal year, Dottikon ES Holding reported revenue of $483M and EBITDA of $181M.
Dottikon ES Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $581M | XXX | $483M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $325M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 67% | XXX | XXX | XXX |
| EBITDA | $212M | XXX | $181M | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 38% | XXX | XXX | XXX |
| EBIT Margin | 30% | XXX | 31% | XXX | XXX | XXX |
| Net Profit | $152M | XXX | $132M | XXX | XXX | XXX |
| Net Margin | 26% | XXX | 27% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Dottikon ES Holding Stock Performance
Dottikon ES Holding has current market cap of $6B, and enterprise value of $6B.
Market Cap Evolution
Dottikon ES Holding's stock price is $457.61.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6B | $6B | 0.3% | XXX | XXX | XXX | $9.58 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDottikon ES Holding Valuation Multiples
Dottikon ES Holding trades at 10.7x EV/Revenue multiple, and 29.4x EV/EBITDA.
EV / Revenue (LTM)
Dottikon ES Holding Financial Valuation Multiples
As of April 3, 2026, Dottikon ES Holding has market cap of $6B and EV of $6B.
Equity research analysts estimate Dottikon ES Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dottikon ES Holding has a P/E ratio of 41.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV/Revenue | 10.7x | XXX | 12.9x | XXX | XXX | XXX |
| EV/EBITDA | 29.4x | XXX | 34.4x | XXX | XXX | XXX |
| EV/EBIT | 35.7x | XXX | 41.7x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 19.2x | XXX | XXX | XXX |
| P/E | 41.5x | XXX | 47.8x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (158.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Dottikon ES Holding Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Dottikon ES Holding Margins & Growth Rates
Dottikon ES Holding's revenue in the last 12 month grew by 21%.
Dottikon ES Holding's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.2M for the same period.
Dottikon ES Holding's rule of 40 is 58% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dottikon ES Holding's rule of X is 89% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Dottikon ES Holding Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | 17% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 58% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 89% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 36% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Dottikon ES Holding Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Chemicals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cogent Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Shanghai Allist | XXX | XXX | XXX | XXX | XXX | XXX |
| Glenmark Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Rhythm Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Laurus Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dottikon ES Holding M&A Activity
Dottikon ES Holding acquired XXX companies to date.
Last acquisition by Dottikon ES Holding was on XXXXXXXX, XXXXX. Dottikon ES Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Dottikon ES Holding
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDottikon ES Holding Investment Activity
Dottikon ES Holding invested in XXX companies to date.
Dottikon ES Holding made its latest investment on XXXXXXXX, XXXXX. Dottikon ES Holding invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Dottikon ES Holding
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Dottikon ES Holding
| When was Dottikon ES Holding founded? | Dottikon ES Holding was founded in 1913. |
| Where is Dottikon ES Holding headquartered? | Dottikon ES Holding is headquartered in Switzerland. |
| How many employees does Dottikon ES Holding have? | As of today, Dottikon ES Holding has over 860 employees. |
| Who is the CEO of Dottikon ES Holding? | Dottikon ES Holding's CEO is Markus Blocher. |
| Is Dottikon ES Holding publicly listed? | Yes, Dottikon ES Holding is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of Dottikon ES Holding? | Dottikon ES Holding trades under DESN ticker. |
| When did Dottikon ES Holding go public? | Dottikon ES Holding went public in 2005. |
| Who are competitors of Dottikon ES Holding? | Dottikon ES Holding main competitors are Cogent Biosciences, Shanghai Allist, Glenmark Pharma, Rhythm Pharmaceuticals. |
| What is the current market cap of Dottikon ES Holding? | Dottikon ES Holding's current market cap is $6B. |
| What is the current revenue of Dottikon ES Holding? | Dottikon ES Holding's last 12 months revenue is $581M. |
| What is the current revenue growth of Dottikon ES Holding? | Dottikon ES Holding revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Dottikon ES Holding? | Current revenue multiple of Dottikon ES Holding is 10.7x. |
| Is Dottikon ES Holding profitable? | Yes, Dottikon ES Holding is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Dottikon ES Holding? | Dottikon ES Holding's last 12 months EBITDA is $212M. |
| What is Dottikon ES Holding's EBITDA margin? | Dottikon ES Holding's last 12 months EBITDA margin is 37%. |
| What is the current EV/EBITDA multiple of Dottikon ES Holding? | Current EBITDA multiple of Dottikon ES Holding is 29.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.